Navigation Links
Hospira Expands Board of Directors
Date:5/13/2008

LAKE FOREST, Ill., May 13 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, announced today that Barbara L. Bowles, CFA, has been elected to the company's board of directors. Bowles brings strong investment management and finance expertise from leadership positions held at major multinational consumer goods companies and equity investment advisory firms. The addition of Bowles expands Hospira's board to nine directors, of whom eight are independent.

"Barbara will be an extraordinary addition to the Hospira board," said Christopher B. Begley, chairman and chief executive officer. "Her broad and deep financial knowledge and corporate policy experience will enhance our current board membership and will be extremely helpful in furthering Hospira's longer-term growth goals."

Bowles, 60, recently retired as vice chair of Profit Investment Management, an investment management firm. Previously, she served as chairman, chief executive officer and chief investment officer of The Kenwood Group, Inc. -- an equity investment advisory corporation that she founded in 1989 -- which was acquired by Profit in January 2006. From 1984 to 1989 she served as corporate vice president of Kraft, Inc., and headed its investor relations department. Earlier in her career, Bowles held equity analyst and trust investment management positions at First National Bank of Chicago (now Chase Bank).

Bowles serves as a director of Black & Decker Corporation, Wisconsin Energy Corporation, Children's Memorial Hospital (Chicago), the Chicago Urban League and Hyde Park Bank. She also is a trustee of Fisk University and the Museum of Science and Industry (Chicago), and serves on the University of Chicago Graduate School of Business Advisory Council. In 2003, she was honored with the "Distinguished Alumni Award" from the African American MBA Association of the University of Chicago.

Bowles is currently pursuing her long-time goal of establishing and funding the Landers-Bowles Family Foundation, which will be primarily focused on charity related to education.

A native of Nashville, Tenn., Bowles holds a master's of business administration degree in finance from the University of Chicago Graduate School of Business, and a bachelor's degree in mathematics, with honors, from Fisk University. She has been a Chartered Financial Analyst (CFA) since 1977.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
3. ATS Medical Expands Open Pivot Heart Valve Offerings
4. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
5. BioLife Solutions Expands Scientific Advisory Board
6. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Pharsight Expands Strategic Consulting Services Team
9. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
10. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
11. AQUISS Expands Into Significant New Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):